Overview

SA4503 8-Week Study in Major Depressive Disorder (MDD)

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of SA4503 compared to placebo in the treatment of subjects with major depressive disorder (MDD). Secondary, to evaluate the safety of SA4503 compared to placebo in subjects with MDD.
Phase:
Phase 2
Details
Lead Sponsor:
M's Science Corporation
Treatments:
SA 4503